Chronic inflammatory demyelinating polyradiculoneuropathy

Presse Medicale

Volumn 42, Issue 6 PART2, 2013, Pages

  Van den Bergh, Peter Y K ^a   Rajabally, Yusuf A ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; MEPREDNISONE; METHOTREXATE; PLACEBO; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR;

ATYPICAL CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; AUTOIMMUNE DISEASE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CYTOKINE PRODUCTION; DEMYELINATION; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; LEUKOCYTE COUNT; MACROPHAGE; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR DYSFUNCTION; MUSCLE ACTION POTENTIAL; NERVE BIOPSY; NERVE CONDUCTION; NERVE PLEXUS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PERIPHERAL NERVOUS SYSTEM FUNCTION; PLASMAPHERESIS; PLEOCYTOSIS; POLYRADICULONEUROPATHY; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; REMISSION; SENSORY DYSFUNCTION; SHORT SURVEY; SPINAL ROOT; STEROID THERAPY; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84879188377     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.01.056     Document Type: Short Survey

References (168)

1. Eichhorst Correspondenz-blatt für Schweizer Ärzte 1890, 20:559.
2. Burns T.M. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2004, 61:973-975.
3. Austin J.H. Recurrent polyneuropathies and their corticosteroid treatment: with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958, 81:157-192.
4. Dyck P.J., Lais A.C., Ohta M., Bastron J.A., Okazaki H., Groover R.V. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975, 50:621-637.
5. Prineas J.W., McLeod J.G. Chronic relapsing polyneuritis. J Neurol Sci 1976, 27:427-458.
6. Dyck P.J., O'Brien P.C., Oviatt K.F., Dinapoli R.P., Daube J.R., Bartlerson J.D., et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136-141.
7. Van Den Bergh P.Y.K., Hadden R.D.M., Bouche P., Cornblath D.R., Hahn A., Illa I., et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First revision. Eur J Neurol 2010, 17:356-363.
8. Brannagan T.H. Current diagnosis of CIDP: the need for biomarkers. J Peripher Nerv Syst 2011, 16 (Suppl.):3-13.
9. Henderson R.D., Sandroni P., Wijdicks E.F. Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol 2005, 252:1235-1237.
10. Stojkovic T., De Seze J., Hurtevent J.F., Fourrier F., Vermersch P. Phrenic nerve palsy as a feature of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2003, 27:497-499.
11. Sakakibara R., Hattori T., Kuwabara S., Yamanishi T., Yasuda K. Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 50:1179-1182.
12. Yamamoto K., Watarai M., Hashimoto T., Ikeda S. Chronic inflammatory demyelinating polyradiculoneuropathy with autonomic involvement. Muscle Nerve 2005, 31:108-112.
13. Boukhris S., Magy L., Li Y., Debras C., Vallat J.M. Autonomic nervous system involvement in chronic inflammatory demyelinating polyneuropathy. Rev Neurol (Paris) 2005, 161:1228-1231.
14. Stamboulis E., Katsaros N., Koutsis G., Iakovidou H., Giannakopoulou A., Simintzi I. Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2006, 33:78-84.
15. Burakgazi A.Z., Alsowaity B., Burakgazi Z.A., Unal D., Kelly J.J. Bladder dysfunction in peripheral neuropathies. Muscle Nerve 2012, 45:2-8.
16. Nevo Y., Pestronk A., Kornberg A.J., Connolly A.M., Yee W.C., Iqbal I., et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 1996, 47:98-102.
17. Simmons Z., Wald J.J., Albers J.W. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve 1997, 20:1008-1015.
18. Simmons Z., Wald J.J., Albers J.W. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve 1997, 20:1569-1575.
19. Hattori N., Misu K., Koike H., Ichimura M., Nagamatsu M., Hirayama M., et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001, 184:57-63.
20. McCombe P.A., Pollard J.D., McLeod J.G. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987, 110:1617-1630.
21. Ruts L., van Koningsveld R., van Doorn P.A. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 2005, 65:138-140.
22. Ruts L., Drenthen J., Jacobs B.C., van Doorn P.A., Dutch G.B.S., Study Group Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome. Neurology 2010, 74:1680-1686.
23. Dionne A., Nicolle M.W., Hahn A.F. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 2010, 41:202-207.
24. Dyck P.J., Dyck P.J.B. Atypical varieties of chronic inflammatory demyelinating neuropathies. Lancet 2000, 355:1293-1294.
25. Vallat J.M., Sommer C., Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010, 9:402-412.
26. Viala K., Maisonobe T., Stojkovic T., Koutlidis R., Ayrignac X., Musset L., et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Periph Nerv Syst 2010, 15:50-56.
27. Lewis R.A., Sumner A.J., Brown M.J., Asbury A.K. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982, 32:958-964.
28. Saperstein D.S., Amato A.A., Wolfe G.I., et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999, 22:560-566.
29. Oh S.J., Claussen G.C., Kim D.S. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 1997, 2:362-369.
30. Jeanjean A.P., Duprez T., Van den Bergh P.Y. Massive peripheral nerve hypertrophy in a patient with multifocal upper limb demyelinating neuropathy (Lewis-Sumner syndrome). Acta Neurol Belg 2001, 101:234-238.
31. Weiss M.D., Oakley J.C., Meekins G.D. Hypoglossal neuropathy in Lewis-Sumner syndrome masquerading as motor neuron disease. Neurology 2006, 67:175-176.
32. Rajabally Y.A., Chavada G. Lewis-Sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve 2009, 39:206-220.
33. Viala K., Renié L., Maisonobe T., Béhin A., Neil J., Léger J.M., et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004, 127:2010-2017.
34. Thomas P.K., Claus D., Jaspert A., Workman J.M., King R.H., Larner A.J., et al. Focal upper limb demyelinating neuropathy. Brain 1996, 119:765-774.
35. Van Den Bergh P.Y., Thonnard J.L., Duprez T., Laterre E.C. Chronic demyelinating hypertrophic brachial plexus neuropathy. Muscle Nerve 2000, 23:283-288.
36. Verma A., Tandan R., Adesina A.M., Pendlebury W.W., Fries T.J., Bradley W.G. Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years. Acta Neurol Scand 1990, 81:516-521.
37. Donaghy M., Mills K.R., Boniface S.J., Simmons J., Wright I., Gregson N., et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994, 57:778-783.
38. Sabatelli M., Madia F., Mignogna T., Lippi L., Quaranta L., Tonali P. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol 2001, 248:772-777.
39. Sinnreich M., Klein C.J., Daube J.R., Engelstad J., Spinner R.J., Dyck P.J. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004, 63:1662-1669.
40. Oh S.J., Joy J.L., Kuruoglu R. Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992, 55:677-680.
41. Berger A.R., Herskovitz S., Kaplan J. Late motor involvement in cases presenting as "chronic sensory demyelinating polyneuropathy". Muscle Nerve 1995, 8:440-444.
42. Thonnard J.L., Detrembleur C., Van den Bergh P.Y.K. Assessment of hand function in a patient with chronic sensory demyelinating neuropathy. Neurology 1997, 49:253-257.
43. van Dijk G.W., Notermans N.C., Franssen H., Wokke J.H. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol 1999, 246:1134-1139.
44. Katz J.S., Saperstein D.S., Gronseth G., Amato A.A., Barohn R.J. Distal acquired demyelinating symmetric neuropathy. Neurology 2000, 54:615-620.
45. Maisonobe T., Chassande B., Verin M., Jouni M., Leger J.M., Bouche P. Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry 1996, 61:36-42.
46. Larue S., Bombelli F., Viala K., Neil K., Maisonobe T., Bouche P., et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011, 18:899-905.
47. Thomas P.K., Walker R.W., Rudge P., Morgan-Hughes J.A., King R.H., Jacobs J.M., et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain 1987, 110:53-76.
48. Willis J., Van Den Bergh P. Cerebral involvement in children with acute and relapsing inflammatory neuropathy. J Child Neurol 1988, 3:200-204.
49. Zéphir H., Stojkovic T., Latour P., Lacour A., de Seze J., Outteryck O., et al. Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry 2008, 79:1032-1039.
50. Ormerod I.E., Waddy H.M., Kermode A.G., Murray N.M., Thomas P.K. Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study. J Neurol Neurosurg Psychiatry 1990, 53:789-793.
51. Pineda A.A., Ogata K., Osoegawa M., Murai H., Shigeto H., Yoshiura T., et al. A distinct subgroup of chronic inflammatory demyelinating polyneuropathy with CNS demyelination and a favorable response to immunotherapy. J Neurol Sci 2007, 255:1-6.
52. Gorson K.C., Allam G., Ropper A.H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997, 48:321-328.
53. Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst 2010, 15:185-195.
54. Vina E.R., Fang A.J., Wallace D.J., Weisman M.H. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum 2005, 35:175-184.
55. Hantson P., Kevers L., Fabien N., Van den Bergh P. Acute-onset chronic inflammatory demyelinating Polyneuropathy with cranial nerve involvement, dysautonomia, respiratory failure, and autoantibodies. Muscle Nerve 2010, 41:423-426.
56. Zappia M., Valentino P., Bono F., Vita G., Aguglia U., Messina C., et al. Chronic inflammatory demyelinating polyneuropathy in patient with rheumatoid arthritis. Eur Neurol 1995, 35:177-179.
57. Lin W.S., Hsu Y.D. Sjögren's syndrome with chronic inflammatory demyelinating polyneuropathy. Neurol India 2011, 59:476-478.
58. Gondim F.A., Brannagan T.H., Sander H.W., Chin R.L., Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 2005, 128:867-879.
59. Smyth S., Menkes D.L. Coincident membranous glomerulonephritis and chronic inflammatory demyelinating polyradiculoneuropathy: questioning the autoimmunity hypothesis. Muscle Nerve 2008, 37:130-135.
60. Echaniz-Laguna A., Anheim M., Wolf P., Kessler R., Massard G., Mohr M., et al. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients with solid organ transplantation: a clinical, neurophysiological and neuropathological study of 4 cases. Rev Neurol (Paris) 2005, 161:1213-1220.
61. Lozeron P., Nahum L., Lacroix C., Ropert A., Guglielmi J.M., Said G. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol 2002, 249:569-575.
62. Rotta F.T., Sussman A.T., Bradley W.G., Ayyar D.R., Sharma K.R., Shebert R.T. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000, 173:129-139.
63. Sharma K.R., Cross J., Farronay O., Ayyar D.R., Shebert R.T., Bradley W.G. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002, 59:758-765.
64. Laughlin R.S., Dyck P.J., Melton L.J., Leibson C., Ransom J. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009, 73:39-45.
65. Chio A., Plano F., Calvo A., Leone M., Mutani R., Cocito D., et al. Comorbidity between CIDP and diabetes mellitus: only a matter of chance?. Eur J Neurol 2009, 16:752-754.
66. Lewis R.A., Sumner A.J., Shy M.E. Electrophysiological features of inherited demyelinating neuropathies: a reappraisal in the era of molecular diagnosis. Muscle Nerve 2000, 23:1472-1487.
67. Pareyson D. Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies. Neurol Sci 2004, 25:72-82.
68. Nicholson G., Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology 1993, 43:2558-2564.
69. Dubourg O., Tardieu S., Birouk N., Gouider R., Léger J.M., Maisonobe T., et al. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. Brain 2001, 124:1958-1967.
70. Van den Bergh P.Y.K., Jacquerye Ph, Piéret F. Electrodiagnosis in demyelinating neuropathies. Acta Neurol Belg 2000, 100:188-195.
71. Dyck P.J., Swanson C.J., Low P.A., Bartleson J.D., Lambert E.H. Prednisone-responsive hereditary motor and sensoryneuropathy. Mayo Clin Proc 1982, 57:239-246.
72. Donaghy M., Sisodiya S.M., Kennett R., McDonald B., Haites N., Bell C. Steroid responsive polyneuropathy in a family with a novel myelin proteinzero mutation. J Neurol Neurosurg Psychiatry 2000, 69:799-805.
73. Houlden H., Laura M., Ginsberg L., Jungbluth H., Robb S.A., Blake J., et al. The phenotype of Charcot-Marie-Tooth disease type 4C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy. Neuromuscul Disord 2009, 19:264-269.
74. Buchthal F., Behse F. Peroneal muscular atrophy (PMA) and related disorders: I. Clinical manifestations as related to biopsy findings, nerve conduction and electromyography. Brain 1977, 100:41-66.
75. Kimura J., Machida M., Ishida T., Yamada T., Rodnitzky R.L., Kudo Y., et al. Relation between size of compound sensory or muscle action potentials, and length of nerve segment. Neurology 1986, 36:647-652.
76. Feasby T.E., Brown W.F., Gilbert J.J., Hahn A.F. The pathological basis of conduction block in human neuropathies. J Neurol Neurosurg Psychiatry 1985, 48:239-244.
77. Logigian E.L., Kelly J.J., Adelman J.S. Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle Nerve 1994, 17:1010-1020.
78. Rajabally Y.A., Jacob S., Hbahbih M. Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. J Peripher Nerv Syst 2005, 10:282-292.
79. Rajabally Y.A., Jacob S. Proximal nerve conduction studies in of chronic inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol 2006, 117:2079-2084.
80. Thaisetthawatkul P., Logigian E.L., Herrmann D.N. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002, 59:1526-1532.
81. Isose S., Kuwabara S., Kokubun N., Sato Y., Mori M., Shibuya K., et al. Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. J Peripher Nerv Syst 2009, 14:151-158.
82. Rajabally YA, Varanasi S. Practical electrodiagnostic value of F-wave studies in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol 2012 Jun 27 [Epub ahead of print].
83. Rajabally Y.A., Narasimhan M. The value of sensory electrophysiology in of chronic inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol 2007, 118:1999-2004.
84. Bragg J.A., Benatar M.G. Sensory nerve conduction slowing is a specific marker for CIDP. Muscle Nerve 2008, 38:1599-1603.
85. Yiannikas C., Vucic S. Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy. Muscle Nerve 2008, 38:447-454.
86. Barohn R.J., Kissel J.T., Warmolts J.R., Mendell J. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendation for diagnostic criteria. Arch Neurol 1989, 46:878-884.
87. De Silva R.N., Willison H.J., Doyle D., Weir A.I., Hadley D.M., Thomas A.M. Nerve root hypertrophy in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 1994, 17:168-170.
88. Ginsberg L., Platts A.D., Thomas P.K. Chronic inflammatory demyelinating polyneuropathy mimicking a lumbar spinal stenosis syndrome. J Neurol Neurosurg Psychiatry 1995, 59:189-191.
89. Midroni G., Dyck P.J. Chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1996, 46:1206-1212.
90. Mizuno K., Nagamatsu M., Hattori N., Yamamoto M., Goto G., Kuniyoshi K., et al. Chronic inflammatory demyelinating polyradiculoneuropathy with diffuse and massive peripheral nerve hypertrophy: distinctive clinical and magnetic resonance imaging features. Muscle Nerve 1998, 21:805-808.
91. Midroni G., de Tilly L.N., Gray B., Vasjar J. MRI of the cauda equina in CIDP: clinical correlations. J Neurol Sci 1999, 170:36-44.
92. van Es H.W., van den Berg L.H., Franssen H., Witkamp T.D., Ramos L.M., Notermans N.C., et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology 1997, 48:1218-1224.
93. Duggins A.J., McLeod J.G., Pollard J.D., Davies L., Yang F., Thompson E.O., et al. Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. Brain 1999, 122:1383-1390.
94. Kuwabara S., Nakajima M., Matsuda S., Hattori T. Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinating polyneuropathy. Neurology 1997, 48:874-877.
95. Adachi Y., Sato N., Okamoto T., Sasaki M., Komaki H., Yamashita F., et al. Brachial and lumbar plexuses in chronic inflammatory demyelinating polyradiculoneuropathy: MRI assessment including apparent diffusion coefficient. Neuroradiology 2011, 53:3-11.
96. Matsuoka N., Kohriyama T., Ochi K., Nishitani M., Sueda Y., Mimori Y., et al. Detection of cervical root hypertrophy by ultrasonography in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004, 219:15-21.
97. Mauermann M.L., Amrami K.K., Kuntz N.L., Spinner R.J., Dyck P.J., Bosch E.P., et al. Longitudinal study of intraneural perineurioma - a benign, focal hypertrophic neuropathy of youth. Brain 2009, 132:2265-2276.
98. Haq R.U., Fries T.J., Pendlebury W.W., Kenny M.J., Badger G.J., Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy. A study of proposed electrodiagnostic and histologic criteria. Arch Neurol 2000, 57:1745-1750.
99. Bouchard C., Lacroix C., Plante V., Adams D., Chedru F., Guglielmi J.M., et al. Clinicopathologic findings and prognosis in chronic inflammatory demyelinating polyneuropathy. Neurology 1999, 52:498-503.
100. Vallat J.M., Tabaraud F., Magy L., Couratier P. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve 2003, 27:478-485.
101. Gabriel C.M., Howard R., Kinsella N., Lucas S., McColl I., Saldanha G., et al. Prospective study of the usefulness of sural nerve biopsy. J Neurol Neurosurg Psychiatry 2000, 69:442-446.
102. Krendel D.A., Parks H.P., Anthony D.C., St Clair M.B., Graham D.G. Sural nerve biopsy in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1989, 12:257-264.
103. Bosboom W.M.J., van den Berg L.H., De Boer L., Van Son M.J., Veldman H., Franssen H., et al. The diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy. Neurology 1999, 53:837-845.
104. Bosboom W.M.J., van den Berg L.H., Franssen H., Giesbergen P.C., Flach H.Z., van Putten A.M., et al. Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy. Brain 2001, 124:2427-2438.
105. Leppert D., Hughes P., Huber S., Erne B., Grygar C., Said G., et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 1999, 53:62-70.
106. Molenaar D.S., Vermeulen M., de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1998, 64:84-89.
107. Jann S., Bramerio M.A., Beretta S., Koch S., Defanti C.A., Toyka K.V., et al. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 2003, 61:1607-1610.
108. Kieseier B.C., Dalakas M.C., Hartung H.P. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002, 59(12 Suppl. 6):S7-S12.
109. Hughes R.A., Bouche P., Cornblath D.R., Evers E., Hadden R.D., Hahn A., et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006, 13:326-332.
110. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Taskforce Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991, 41:617-618.
111. Olney R.K. Guidelines in electrodiagnostic medicine: consensus criteria for the diagnosis of partial conduction block. Muscle Nerve 1999, 22:S225-S229.
112. Saperstein D.S., Katz J.S., Amato A.A., Barohn R.J. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001, 24:311-324.
113. Hughes R., Bensa S., Willison H., Van den Bergh P., Comi G., Illa I., et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195-201.
114. Van den Bergh P.Y.K., Piéret F. Electrodiagnostic criteria for acute and chronic demyelinating polyradiculoneuropathy. Muscle Nerve 2004, 29:565-574.
115. Bromberg M.B. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991, 10:968-976.
116. Albers J.W., Kelly J.J. Acquired demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989, 12:435-451.
117. Nicolas G., Maisonobe T., Le Forestier N., Léger J.M., Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002, 25:26-30.
118. van Asseldonk J.T.H., van den Berg L.H., Kalmijn S., Wokke J.H.J., Franssen H. Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37°C: diagnostic yield in chronic inflammatory demyelinating polyneuropathy. Brain 2005, 128:880-891.
119. Rajabally Y.A., Nicolas G., Piéret F., Bouche P., Van den Bergh P.Y.K. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry 2009, 80:1364-1368.
120. Tackenberg B., Lünemann J.D., Steinbrecher A., Rothenfusser-Korber, Sailer M., Brück W., et al. Classifications and treatment responses in immune-mediated demyelinating polyneuropathy. Neurology 2007, 68:1622-1629.
121. Koski C.L., Baumgarten M., Magder L.S., Barohn R.J., Goldstein J., Graveset M., et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2009, 277:1-8.
122. Lunn M.P., Manji H., Choudhary P.P., Hughes R.A., Thomas P.K. Chronic inflammatory demyelinating polyneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999, 66:677-680.
123. McLeod J.G., Pollard J.D., Macaskill P., Mohamed A., Spring P., Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999, 46:910-913.
124. Chio A., Cocito D., Bottacchi E., Buffa C., Leone M., Plano F., et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007, 78:1349-1353.
125. Albers J.W., Kelly J.J. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989, 12:435-451.
126. Mygland Å., Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001, 8:157-165.
127. Rajabally A., Simpson B.S., Beri S., Bankart O., Gosalakkal J.A. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: Study of a UK population. Muscle Nerve 2009, 39:432-438.
128. Mahdi-Rogers M., Al-Chalabi A., Hughes R.A.C. Prevalence and morbidity of chronic inflammatory neuropathies in South East England. J Periph Nerv Syst 2008, 13(Suppl. 2):176.
129. Dalakas M.C. Autoimmune peripheral neuropathies. clinical immunology: principles and practice 2008, 977-994. Mosby Elsevier, Philadelphia. 3rd ed. R.R. Rich, T.A. Fleisher, W.T. Shearer (Eds.).
130. Winer J., Hughes S., Cooper J., Ben-Smith A., Savage C. Gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 2002, 249:616-621.
131. Hartung H.P., Reiners K., Schmidt B., Stoll G., Toyka K.V. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991, 30:48-53.
132. Misawa S., Kuwabara S., Mori M., Kawaguchi N., Yoshiyama Y., Hattori T. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 2001, 56:666-669.
133. Sommer C., Koch S., Lammens M., Gabreels-Festen A., Stoll G., Toyka K.V. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 2005, 65:1924-1929.
134. Kieseier B.C., Tani M., Mahad D., Oka N., Ho T., Woodroofe N., et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002, 125:823-834.
135. Mahad D.J., Howell S.J., Woodroofe M.N. Expression of chemokines in cerebrospinal fl uid and serum of patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002, 73:320-323.
136. van Rhijn I., van den Berg L.H., Bosboom W.M., Otten H.G., Logtenberg T. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain 2000, 123:2020-2029.
137. Chi L.J., Wang H.B., Wang W.Z. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2008, 13:54-63.
138. Notturno F., Pace M., De Angelis M.V., Caporale C.M., Giovannini A., Uncini A. Susceptibility to chronic inflammatory demyelinating polyradiculoneuropathy is associated to polymorphic GA repeat in the SH2D2A gene. J Neuroimmunol 2008, 197:124-127.
139. Yan W.X., Taylor J., Andrias-Kauba S., Pollard J.D. Passive transfer of demyelination by serum or IgG from chronic inflamatory demyelinating polyneuropathy patients. Ann Neurol 2000, 47:765-775.
140. Dalakas M.C., Engel W.K. Immunoglobulin and complement deposits in nerves of patients with chronic relapsingpolyneuropathy. Arch Neurol 1980, 37:637-640.
141. Yan W.X., Archelos J.J., Hartung H.P., Pollard J.D. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:286-292.
142. Sanvito L., Makowska A., Mahdi-Rogers M., Hadden R.D., Peakman M., Gregson N., et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2009, 80:333-338.
143. Ng J.K.M., Malotka J., Kawakami N., Derfus T., Khademi M., Olsson T., et al. Neurofascin as a target for autoantibodies in peripheralneuropathies. Neurology 2012, 79:2241-2248.
144. Hahn A.F. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 1998, 51(6 Suppl. 5):S16-S21.
145. Mendell J.R., Barohn R.J., Freimer M.L., Kissel J.T., King W., Nagaraja H.N., et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445-449.
146. Thompson N., Choudhary P., Hughes R.A., Quinlivan R.M. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996, 243:280-285.
147. Kubori T., Mezaki T., Kaji R., Kimura J., Hamaguchi K., Hirayama K., et al. The clinical usefulness of highdose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No To Shinkei 1999, 51:127-135.
148. Vermeulen M., van Doorn P.A., Brand A., Strengers P.F., Jennekens F.G., Busch H.F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993, 56:36-39.
149. van Doorn P.A., Brand A., Strengers P.F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990, 40:209-212.
150. Dyck P.J., Litchy W.J., Kratz K.M., Suarez G.A., Low P.A., Pineda A.A., et al. A plasma exchange versus immuneglobulin infusion trial in chronic inflamatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36:838-845.
151. Nobile-Orazio E., Cocito D., Jann S., Uncini A., Beghi E., Messina P., et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyneuropathy: a randomised controlled trial. Lancet Neurol 2012, 11:493-502.
152. Hughes R.A., Donofrio P., Bril V., Dalakas M.C., Deng C., Hanna K., et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008, 7:136-144.
153. Rajabally Y.A., Seow H., Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2006, 11:325-329.
154. RMC Trial Group Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009, 8:158-164.
155. van Schaik I., Eftimov F., van Doorn P.A., Brusse E., van den Berg L.H., van der Pol W.L., et al. Pulsed high-dose dexamethasone versus standard prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9:245-253.
156. Eftimov F., Vermeulen M., van Doorn P.A., Brusse E., van Schaik IN PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-tern prednisolone treatment. Neurology 2012, 78:1079-1084.
157. van Schaik I. First-line treatment for CIDP: a new piece of the puzzle. Lancet Neurol 2012, 11:478-479.
158. Dyck P.J., Daube J., O'Brien P., Pineda A., Low P.A., Windebank A.J., et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461-465.
159. Hahn A.F., Bolton C.F., Pillay N., Chalk C., Benstead T., Bril V., et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055-1066.
160. Cocito D., Paolasso I., Antonini G., Benedetti L., Briani C., Comi C., et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic demyelinating inflammatory polyradiculoneuropathy. Eur J Neurol 2010, 17:289-294.
161. Cocito D., Grimaldi S., Paolasso I., Falcone Y., Antonini G., Benedetti L., et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyneuropathy. A nationwide retrospective analysis. Eur J Neurol 2011, 18:1417-1421.
162. Mahdi-Rogers M., Swan A.V., van Doorn P.A., Hughes R.A. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2010, 11:CD003280.
163. Gladstone D.E., Prestrud A.A., Brannagan T.H. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005, 10:11-16.
164. Odaka M., Tatsumoto M., Susuki K., Hirata K., Yuki N. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 2005, 76:1115-1120.
165. Radziwill A.J., Schweikert K., Kuntzer T., Fuhr P., Steck A.J. Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: an open-label study. Eur Neurol 2006, 56:37-38.
166. Benedetti L., Briani C., Franciotta D., Fazio R., Paolasso I., Comi C., et al. Rituximab in patients with chronic inflammatory demyelinating polyneuropathy: a report of 13 cases and a review of the literature. J Neurol Neurosurg Psychiatry 2011, 83:306-308.
167. Mahdi-Rogers M., Kazmi M., Ferner R., Hughes R.A., Renaud S., Steck A.J., et al. Autologous peripheral blood stem cell transplant for chronic acquired demyelinating polyneuropathy. J Peripher Nerv Syst 2009, 14:118-124.
168. Gorson K.C., van Schaik I.N., Merkies I.S., Lewis R.A., Barohn R.J., Koski C.L., et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010, 15:326-333.